Mode
Text Size
Log in / Sign up

Efficacy of High-Intensity Interval Training and Moderate-Intensity Continuous Training in MASLDExercise Types Improve Liver Health in MASLD Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Both HIIT and MICT effectively improve liver markers and metabolic parameters in MASLD patients with high feasibility.

This meta-analysis evaluates the clinical impact of two distinct exercise modalities—High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT)—on patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). By analyzing data from 1,546 participants, the study aims to determine the efficacy and feasibility of these interventions in managing hepatic fat accumulation and associated metabolic risks.

Findings indicate that HIIT provides robust improvements across multiple clinical domains. Specifically, patients undergoing HIIT showed significant improvements in body composition and cardiometabolic parameters. These improvements are critical for managing the systemic complications often associated with fatty liver disease. Furthermore, liver markers showed significant improvement in the HIIT cohort, suggesting a positive impact on hepatic health.

MICT also demonstrated positive outcomes for patients with MASLD. While the magnitude of improvement in liver markers was slightly lower than that observed in the HIIT group, MICT still provided statistically significant benefits for body composition and cardiometabolic parameters. This suggests that while both modalities are effective, the intensity of the intervention may influence the degree of physiological adaptation.

A comparative analysis of lipid profiles revealed that HIIT was superior to MICT in reducing total cholesterol levels. This specific finding highlights the potential of high-intensity protocols to more aggressively target lipid profiles in patients with metabolic dysfunction. The data suggests that for patients requiring rapid lipid modification, HIIT may be the preferred intervention.

From a clinical standpoint, the feasibility of both exercise modalities is high. The study reported high adherence rates (83.4%) and completion rates (83.9%) for the interventions. This is a crucial finding for clinicians, as patient compliance is often a barrier to long-term management of metabolic liver diseases. Both programs were noted to have a high safety profile.

In conclusion, both HIIT and MICT are viable and safe options for managing MASLD. While both modalities improve body composition and metabolic markers, HIIT may offer superior results in specific areas such as cholesterol reduction. Clinicians can recommend either based on patient preference, fitness levels, and specific goals regarding lipid management or liver enzyme stabilization.

How this fits prior evidence

How this fits prior evidence This meta-analysis complements existing evidence for MASLD management by providing a non-pharmacological intervention. While previous findings noted that telmisartan reduces fasting blood sugar in MASLD and empagliflozin shows promise in reducing steatosis and fibrosis markers in preclinical models, this study confirms that both HIIT and MICT effectively improve liver markers and cardiometabolic parameters in human patients. It addresses a gap by providing evidence for exercise-based interventions to improve both metabolic and hepatic outcomes.

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is a condition where fat builds up in the liver. It is often linked to being overweight, having diabetes, or high cholesterol. Exercise is known to help, but which type is best? A new meta-analysis looked at two common exercise programs: high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT). HIIT involves short bursts of intense activity followed by rest, while MICT is steady exercise like brisk walking or cycling at a moderate pace.

The study combined results from 1546 patients with MASLD. It found that both HIIT and MICT significantly improved body composition, such as reducing fat and increasing muscle. They also improved cardiometabolic parameters, like blood sugar and blood pressure. Most importantly, both types of exercise improved liver markers, which are blood tests that show liver health. The improvements were meaningful, with effect sizes ranging from moderate to large.

When comparing the two, HIIT was superior to MICT for lowering total cholesterol. This is important because high cholesterol is a common problem in MASLD patients. However, both types of exercise were effective overall. The study also looked at how feasible these programs are. Adherence, meaning how well patients stuck to the program, was 83.4%, and completion was 83.9%. This shows that both HIIT and MICT are practical for patients to do.

Safety was also good. The study reported that safety was relatively high, with no serious adverse events mentioned. This is reassuring for patients and doctors. The findings suggest that patients with MASLD can choose the exercise type that fits their preferences and abilities. Some may enjoy the variety of HIIT, while others may prefer the steady pace of MICT.

It is important to note that this was a meta-analysis of controlled trials, meaning the results are strong. However, the study did not report specific limitations or funding sources. Also, there was a note about a dose-response for liver enzymes beyond a certain amount of exercise per session, but this was not detailed. Overall, the takeaway is clear: regular exercise, whether HIIT or MICT, can significantly improve liver health and overall well-being in MASLD patients.

In practice, doctors can recommend either HIIT or MICT based on patient preference. The key is to start slowly and gradually increase intensity. Patients should also combine exercise with a healthy diet and other lifestyle changes for the best results. This study provides strong evidence that exercise is a powerful tool in managing MASLD.

What this means for you:
Both HIIT and MICT are safe, feasible, and effective for improving liver health and metabolic parameters in MASLD patients.

Study Details

Study typeMeta analysis
Sample sizen = 1,546
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
PURPOSE: This meta-analysis evaluated the efficacy and feasibility of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and identified key moderators. METHODS: Controlled trials were systematically searched (PubMed, Web of Science, CNKI; initially in Feb 2025 and updated Jan 2026). Random-effects meta-analyses used SMDs; risk of bias, methodological quality, and evidence certainty were systematically assessed. RESULTS: Thirty-seven trials (1546 participants, 51% female, moderate quality) showed HIIT significantly improved 12 outcomes vs. controls, including body composition (g - 0.94 to -0.52), cardiometabolic parameters (-1.56 to 1.34), and liver markers (-1.06 to -0.50), while MICT benefited 18 outcomes, including body composition (-0.84 to -0.60), cardiometabolic parameters (-1.42 to 1.79), and liver markers (-0.72 to -0.67). HIIT was superior for total cholesterol reduction (g - 0.44, p < 0.05). Subgroup analyses identified significant moderation by obesity status, training frequency, exercise modality, and progression. Meta-regression revealed MICT effects moderated by age, BMI, and prescription parameters (e.g., session duration, weekly time, program length), with significant associations for body fat, lipids, and glycemic control changes. Exploratory nonlinear meta-regression showed distinct dose-response patterns for liver enzyme biomarker improved emerging beyond baseline, 260-280 MET-min per MICT session. Feasibility was high (adherence 83.4%, completion 83.9%), and safety was relatively high. CONCLUSION: Both HIIT and MICT effectively improve anthropometric, metabolic parameters, and liver function indicators in patients with MASLD, while demonstrating high feasibility and safety. Moderators' analyses identified key moderators and dose-response, informing evidence-based exercise prescription considerations for MASLD management. REGISTERED: PROSPERO (CRD42025646755).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.